Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 6.3% in the afternoon session after Cigna Group's Evernorth ...

Hims & Hers (NYSE: HIMS) has put investors on a roller coaster ride in 2025. *Stock prices used were the afternoon prices of ...

Hims & Hers Health (HIMS) has captured significant market attention in 2025 with its dramatic stock swings, starting the year ...

Hims & Hers Health continues to fire on all cylinders as a business. Click here to read why HIMS stock is a Buy.

Hims & Hers has delivered strong results and partnerships, but recent Cigna/Novo Nordisk news increases competitive risk and ...

Just 14 stocks with market caps above $1 billion have doubled so far this year. They probably aren't the winners you would ...

S&P 500, Northern Trust Corporation, Unitedhealth Group, Hims Hers Health Inc. Read 's Market Analysis on Investing.com ...

Hims & Hers Health, Inc (NYSE:HIMS) is facing heavy selling pressure Thursday morning as the U.S. Food and Drug Administration's (FDA) ban of compounded drugs with semaglutide takes effect.

Stay on our website for longer than five minutes and you’re bound to find references to Schaeffer’s Volatility Scorecard (SVS ...

Hims & Hers Health (HIMS) has received mixed ratings from Top Wall Street analysts, with Morgan Stanley (MS) maintaining a Hold rating while Citi (C) reiterates a Sell rating. The company’s strong app ...

Here are the latest stock rating downgrades by Seeking Alpha analysts: Nvidia (NASDAQ:NVDA). Buy to hold by Oakoff ...